CRSP CRISPR Therapeutics AG
Price Chart
Executive Summary
CRISPR Therapeutics held its 2026 Annual General Meeting on June 4, 2026, where shareholders approved routine items including the re-election of all 11 board members, the 2026 Stock Option and Incentive Plan, amendments to the articles of association, and increases to the capital band and conditional share capital. No financial results, guidance, or material operational updates were disclosed — this is a standard governance filing with no immediate trading catalyst.
Actionable Insight
This is a routine annual meeting filing with no material financial or operational news. Monitor upcoming quarterly results for pipeline updates on CASGEVY and other gene-editing programs, which are the primary catalysts for CRSP.
Key Facts
- Shareholders approved the CRISPR Therapeutics AG 2026 Stock Option and Incentive Plan, replacing the 2018 Plan.
- All 11 incumbent directors were re-elected, including CEO Samarth Kulkarni as chairman.
- Shareholders approved an increase to the company's capital band and conditional share capital for convertible instruments.
- Amended articles of association were approved and become effective upon Swiss commercial register registration on or about June 5, 2026.
- Ernst & Young AG and Ernst & Young LLP were re-elected as statutory auditor and independent registered public accounting firm, respectively.
- No financial results, revenue figures, earnings, or guidance were reported in this filing.
Financial Impact
No financial impact — routine governance and compensation plan renewal.
Risk Factors
- No immediate risks identified from this filing.
- Equity dilution risk from the new 2026 Stock Option and Incentive Plan is standard and not material at this stage.
Market Snapshot
Documents Analyzed
This report is based on 12 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-257593 |
| Document: crsp-20260604.htm | 0001193125-26-257593 |
| Document: crsp-ex10_1.htm | 0001193125-26-257593 |
| Document: crsp-ex10_2.htm | 0001193125-26-257593 |
| Document: crsp-ex10_3.htm | 0001193125-26-257593 |
| Document: crsp-ex10_4.htm | 0001193125-26-257593 |
| Document: crsp-ex10_5.htm | 0001193125-26-257593 |
| Document: crsp-ex10_6.htm | 0001193125-26-257593 |
| Document: crsp-ex10_7.htm | 0001193125-26-257593 |
| Document: 0001193125-26-257593-index-headers.html | 0001193125-26-257593 |
| Document: 0001193125-26-257593-index.html | 0001193125-26-257593 |
| Document: 0001193125-26-257593.txt | 0001193125-26-257593 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 4, 2026
10d ago
|
8-K
| $56.90 awaiting T+20 | awaiting T+20 | — | $49.80 (−12.48%) |
|
May 4, 2026
5w ago
|
8-K
| $52.38 $52.02 | ▲ +0.69% | ▲ +5.64% | $49.80 (+4.93%) |
|
Apr 21, 2026
7w ago
|
DEFA14A
| $55.54 $48.56 | ▼ −12.57% | ▼ −17.48% | $49.80 (−10.33%) |
|
Mar 16, 2026
13w ago
|
Insider Cluster
| $48.42 $56.86 | ▲ +17.43% | ▲ +13.65% | $49.80 (+2.85%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access